Galapagos NV Description
Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn's disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.
Classification
Sector:
Healthcare
Industry:
Biotechnology
Keywords:
Medicine
Immunology
Acid
Autoimmune Disease
Clinical Development
Inflammation
Monoclonal Antibodies
Inflammatory Diseases
Psoriasis
Rheumatoid Arthritis
Inflammatory Bowel Disease
Ulcerative Colitis
Osteoarthritis
Ulcer
Cystic Fibrosis
Abdominal Pain
Colitis
Arthritis
Fatty Acids
Treatment Of Inflammatory Disease
Treatment Of Inflammatory Diseases
Janus Kinase
Morphosys
Treatment Of Inflammation